

Biosketch of Gizem Dinler-Doganay

Gizem Dinler-Doganay received her undergraduate degree in Chemistry from Bogazici University in 2000 and went to University of Massachusetts, Amherst for her PhD studies. After completing protein folding and protein dynamic analysis related studies at Prof. Gierasch's Lab in 2006, she started working at Sabanci University in 2006 and conducted research in both biophysics and molecular biology related areas. Dinler-Doganay started to work as an assistant professor in Istanbul Technical University (ITU), Molecular Biology and Genetics Department in the first months of 2009 and continued there since today as an associate professor from 2013. In 2017, she has become a board member of the Molecular Biology Association of Turkey. She is also one of the founding members of the Turkish Proteomics Association and is an active member of this association since 2012.

After establishing her own research lab in 2009 at ITU, she graduated more than 30 graduate students from her lab and led 6 TUBITAK projects as a principal investigator (3 of which are still active), participated in 2 TUBITAK projects as a consultant and directed 2 ISTKA projects as ITU coordinator. She has also been involved in more than 30 ITU internally funded projects as a project coordinator. She has more than 30 scientific peer-reviewed manuscripts.

Dinler-Doganay pursues her studies by combining molecular biology problems with structural biology related approaches. She has been involved in a TUBITAK project that is held with a pharmaceutical company to develop a biosimilar antibody since 2015. She heavily took role in the downstream development processes and the analytical characterization of the products. One product has already been in the pre-clinical phase, and in the pipeline there are two more products awaiting. She is also the co-founder of Genomic Laboratory (GLAB) which was established in 2015 with joint efforts of the Ministry of Health of Turkey and ITU as a non-profit organization. This collaborative laboratory now serves as the genetic center of the entire Anatolian site of Istanbul, approximately serving 7 million people. Currently, Dinler-Doganay established her own start-up as Genome and Drug Development Pharma (GDD Pharma) and there she aims to produce inhibitors targeting the critical signaling sites at protein-protein interfaces.